leadf
logo-loader
viewANGLE PLC

ANGLE CEO reports 'progress across multiple fronts' and talks big new opportunity in immunotherapy

ANGLE PLC's (LON:AGL) (OTCQX:ANPCY) Andrew Newland speaks to Proactive to update on progress since the COVID-19 lockdown began.

He says a key focus during the period has been on finalising the significant amount of written documentation and analysis for the firm’s imminent submission to the US Food & Drug Administration.

Newland also discusses how he believes its ground-breaking liquid biopsy system could have a role to play helping guide trials in cancer immunotherapies.

Quick facts: ANGLE PLC

Price: 43.5 GBX

AIM:AGL
Market: AIM
Market Cap: £93.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read